Congress Pushes Mylan For A Lot More Details On EpiPen Profit
Congress wants more documents — lots and lots more documents — about how much the big drug company Mylan makes on its EpiPens.
A congressional committee Monday asked Mylan for a wide range of additional documentation related to the profitability of EpiPen auto-injectors amid questions about how much taxes the company actually pays on sales of the lifesaving anti-allergy devices.
The letter lists 18 different sets of information requested by the House Oversight and Government Reform Committee. And the committee wants all of that by Friday.
A congressional committee Monday asked Mylan for a wide range of additional documentation related to the profitability of EpiPen auto-injectors amid questions about how much taxes the company actually pays on sales of the lifesaving anti-allergy devices.
The letter lists 18 different sets of information requested by the House Oversight and Government Reform Committee. And the committee wants all of that by Friday.